Select Investment Series III SICAV - T. Rowe Price Health Sciences Equity Fund E (GBP) Fonds
|
|
WKN DE: A40U4X / ISIN: LU2926262150
Anlageziel
To increase the value of its shares, over the long term, through growth in the value of, and income from, its investments. The fund is actively managed and invests mainly in a diversified portfolio of shares of companies that are involved in the research, development, production, or distribution of products or services related to health sciences. The companies may be anywhere in the world, including emerging markets, with a focus on companies in the United States.
Stammdaten
| WKN | A40U4X |
| ISIN | LU2926262150 |
| Fondsgesellschaft | T. Rowe Price Management |
| Kategorie | Branchen: Gesundheitswesen |
| Währung | GBP |
| Mindestanlage | |
| VL-fähig? | Nein |
| Thesaurierend/Ausschüttend | Thesaurierend |
| Fondsmanager | Ziad Bakri |
Aktuelle Daten
| Fondsnote | - |
| Aktueller Rücknahmepreis | 9,67 |
| Fonds Volumen | 70 188 558,39 |
| Total Expense Ratio (TER) | 0,77 |
Gebühren
| Verwaltungsgebühr | % |
| Depotbankgebühr | % |
| Rücknahmegebühr | % |
| Ausgabeaufschlag | % |
Basisdaten
| Auflagedatum | 29.11.2024 |
| Depotbank | J.P. Morgan SE, Luxembourg Branch |
| Zahlstelle | |
| Domizil | Luxembourg |
| Geschäftsjahr | 31.12.2025 |
Performancedaten
| Veränderung Vortag | -0,04 |